Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




High-Sensitivity Troponin I Explored Post-Cardiac Surgery

By LabMedica International staff writers
Posted on 07 Mar 2022
Print article
Image: The Architect STAT Troponin-I assay is a 2-step chemiluminescent microparticle immunoassay designed to detect cardiac troponin I (cTnI) in serum and plasma using the ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics)
Image: The Architect STAT Troponin-I assay is a 2-step chemiluminescent microparticle immunoassay designed to detect cardiac troponin I (cTnI) in serum and plasma using the ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Diagnostics)

Consensus recommendations regarding the threshold levels of cardiac troponin elevations for the definition of perioperative myocardial infarction and clinically important periprocedural myocardial injury in patients undergoing cardiac surgery range widely.

Although cardiac surgery has the potential to improve the quality and prolong the duration of a patient’s life, it is associated with complications. Prognostically important myocardial injury, detected by an elevated concentration of either cardiac troponin or creatine kinase MB4, is one of the most common complications after cardiac surgery and is associated with increased mortality.

A large international team of clinical scientists led by those from McMaster University (Hamilton, ON, USA) recruited patients from a convenience sample of 24 hospitals in 12 countries from May 2013 through April 2019. Patients were enrolled from North America (35.9%), Asia (28.3%), Europe (26.2%), South America (6.3%), and Australia (3.3%). The mean age of the study cohort was 63.3 years, 70.9% of the patients were men, 29.3% had a history of myocardial infarction, and 70.2% were White. Blood samples were obtained for measurement of cardiac troponin I levels with the ARCHITECT STAT assay (Abbott Laboratories, Abbott Park, IL, USA), (upper reference limit, 26 ng/L; limit of detection, 1 to 2 ng/L liter) before surgery, 3 to 12 hours after surgery, and on days 1, 2, and 3 after surgery.

The team reported that within the first day after surgery, troponin was measured in 13,662 patients. Among these patients, 13,316 patients (97.5%) had a peak troponin measurement of more than 260 ng/L (>10 times the upper reference limit), 12,217 patients (89.4%) had a peak troponin measurement of at least 910/L (≥35 times the upper reference limit), and 10,205 patients (74.7%) had a peak troponin measurement of at least 1,820 ng/L (≥70 times the upper reference limit). By 30 days after surgery, 296 patients (2.1%) had died and 399 patients (2.9%) had had a major vascular complication. Among patients who underwent other cardiac surgery, the corresponding threshold troponin level was 12,981 ng/L (95% CI, 2673 to 16,591), a level 499 times the upper reference limit.

The authors concluded that the levels of high-sensitivity troponin I after cardiac surgery that were associated with an increased risk of death within 30 days were substantially higher than levels currently recommended to define clinically important periprocedural myocardial injury. The study was published on March 3, 2022 in the journal The New England Journal of Medicine.

Related Links:
McMaster University 
Abbott Laboratories 

 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.